Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Calcifying epithelial odontogenic tumor (CEOT), first identified by Jens Jorgen Pindborg in 1955, is a rare developmental odontogenic tumor, accounting for approximately 0.4% of all such tumors and most commonly occurring in the third and fourth decades of life. A 63-year-old man presented with a painful swelling in the right lower face, which had progressively enlarged over four months. Clinical and radiological findings revealed a dentoalveolar abscess with an osteolytic lesion mimicking involving the mandibular ramus and an impacted tooth. Histopathological examination confirmed CEOT. This case is notable due to its unusual presentation, mimicking dental osteomyelitis and occurring in an older individual, emphasizing the need for thorough diagnostic evaluation in atypical cases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11888624 | PMC |
| http://dx.doi.org/10.4103/jpbs.jpbs_1293_24 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Use of a masseter fascia transposition flap for ventral orbital stabilization after partial inferior orbitectomy in a dog.
Can Vet J
September 2025
Department of Clinical Sciences, College of Veterinary Medicine, Kansas State University, 1800 Denison Avenue, Manhattan, Kansas 66506, USA.
A 12-year-old neutered male pit bull crossbreed dog was presented because of a right caudal maxillary swelling. Computed tomographic imaging of the skull and revealed a right maxillary mass with lysis of the medial wall of the right orbit and rostral aspect of the zygomatic bone. A biopsy was done, and histopathology results were consistent with a mixed odontogenic tumor.
View Article and Find Full Text PDFAdenomatoid Odontogenic Tumor Arising From a Dentigerous Cyst in a 10-Year-Old Patient: A Case Report and Literature Review.
Cureus
August 2025
Craniomaxillofacial Surgery, Amrita Institute of Medical Sciences, Kochi, IND.
Adenomatoid odontogenic tumor (AOT) is a benign, well-encapsulated odontogenic lesion that typically presents as a slow-growing, asymptomatic mass. Surgical enucleation or curettage remains the treatment of choice due to the tumor's non-invasive nature and well-defined borders, which facilitate complete removal with minimal risk of recurrence. Interestingly, some studies have suggested that AOTs may occasionally arise within pre-existing dentigerous cysts, indicating a possible developmental relationship between the two entities.
View Article and Find Full Text PDFTenascin-C expression in relation to tumor-stroma interaction in ameloblastoma.
Lab Invest
September 2025
Section of Pediatric Dentistry, Department of Oral Growth and Development, Fukuoka Dental College, Fukuoka, Japan; Oral Medicine Research Center, Fukuoka Dental College, Fukuoka, Japan.
Ameloblastoma (AM) is a benign epithelial odontogenic tumor that occurs in the jawbone. Although benign, AM can exhibit aggressive features, including locally invasive growth. Additionally, local recurrence or distant metastasis may occur.
View Article and Find Full Text PDFOdontomas as a cause of tooth eruption disorders.
Dent Med Probl
September 2025
The Children's Memorial Health Institute, Warsaw, Poland.
Background: Odontomas are odontogenic tumors located in the jawbone, referred to by the World Health Organization (WHO) as hamartomatous (Greek hamartion - a bodily defect) developmental malformations. The term was first used by Brock in 1866 to refer to every odontogenic tumor. Today an odontoma is believed to be a congenital malformation of dental hard tissues.
View Article and Find Full Text PDFMolecular-targeted therapy in ameloblastoma: a systematic review.
Arch Craniofac Surg
August 2025
Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Universitas Indonesia, Jakarta, Indonesia.
Background: Ameloblastoma is a benign odontogenic tumor that predominantly occurs in the mandible and is frequently associated with the BRAFV600E mutation, which activates the mitogen-activated protein kinase (MAPK) signaling pathway. These mutations indicate potential targets for molecular therapies. This systematic review evaluated the effectiveness of molecular-targeted therapies, particularly BRAF inhibitors such as dabrafenib and vemurafenib, in the treatment of ameloblastoma and their effects on clinical outcomes and quality of life.
View Article and Find Full Text PDF